Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OneDose is a proprietary extended-release drug delivery platform developed by Crescent Innovations, specifically designed for post-surgical pain management. The technology is engineered to provide a single-dose administration that maintains drug release for approximately 24 hours, aiming to bridge the critical early post-operative period where pain management is most intensive. While the platform is a key component of Crescent Innovations' pipeline, the specific active pharmaceutical ingredients and molecular targets associated with the OneDose system have not been publicly disclosed. The development of the platform has been supported by SBIR grants, with Phase 1 complete and Phase 2 pending as of the latest reports.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OneDose.